Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
Open Orphan plc has changed its name to hVIVO plc (Ticker: HVO)
Watch hVIVO’s Capital Markets Day 2022 presentation here.
Yamin 'Mo' Khan
CEO at hVIVO
We are the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. We provide end-to-end services to our diverse portfolio of clients, including four of the top 10 global biopharma companies. I look forward to driving further growth across the business this year and converting this substantial progress into value for our shareholders.
Rapidly Growing
Specialist CRO
Leader in Human
Challenge Trials
Operational
Excellence
Well Positioned
for Growth
hVIVO is the world leader in testing infectious and respiratory disease products using human challenge study models
Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.
FluCamp welcome volunteers to take part in our clinical trials under expertly supervised conditions.
